Main Page Side Effects Insurance Coverage Review Board

Does Blue Cross Blue Shield Minnesota Cover Ozempic for Weight Loss?

Does Blue Cross Blue Shield Minnesota Cover Ozempic? Minnesota BCBS Coverage Guide 2026

For Minnesota residents trying to find out if your Blue Cross Blue Shield plan covers Ozempic, coverage varies based on several key factors. Blue Cross Blue Shield of Minnesota administers coverage for hundreds of thousands of Minnesota residents, and their formulary handling of Ozempic (semaglutide) differs from national BCBS guidelines.


BCBS Minnesota Formulary Status for Ozempic

Blue Cross Blue Shield of Minnesota maintains a drug list that can diverge from national BCBS formularies. Currently, Ozempic is generally classified as Tier 4 (preferred specialty brand) on most Blue Cross Blue Shield of Minnesota commercial plans.

The practical impact is:

  • Prior authorization is required before coverage activates
  • Step therapy is often required — you’ll need to fail formulary-preferred drugs first
  • Out-of-pocket costs usually land between $50–$150/month based on plan design and deductible status
  • Select Minnesota employer-sponsored BCBS plans may cover Ozempic at a lower tier

Without insurance, Ozempic costs $850–$1,200 per month statewide.


Ozempic Coverage for Medical Conditions in Minnesota

Blue Cross Blue Shield of Minnesota’s coverage policies for Ozempic depend heavily on the diagnosis.

For type 2 diabetes (FDA-approved indication):

  • Approval is more likely
  • The majority of Minnesota BCBS plans cover Ozempic when medical necessity is demonstrated
  • PA criteria generally requires HbA1c levels above 7%

For weight loss (off-label for some formulations):

  • Blue Cross Blue Shield of Minnesota applies stricter criteria
  • You must demonstrate BMI ≥30 (or ≥27 with at least one weight-related comorbidity)
  • Many Minnesota plans exclude GLP-1s for obesity

How to Get Ozempic Approved by BCBS Minnesota

Securing coverage for Ozempic through Blue Cross Blue Shield of Minnesota involves careful preparation.

  1. Check your plan’s formulary — Contact member services to confirm Ozempic’s coverage status on your specific plan
  2. Coordinate with your prescriber submit prior authorization — Attach diagnosis codes, lab results, and prior medication history
  3. Document failed prior therapies — BCBS Minnesota’s rules may need documentation of failed multiple first-line treatments first
  4. Challenge a denial — Blue Cross Blue Shield of Minnesota allows two levels of internal appeal plus independent review via

Research shows that around one-third of GLP-1 prior authorization requests face first-round denial but a majority win on appeal.


What to Do After a Denial

When Blue Cross Blue Shield of Minnesota won’t approve Ozempic coverage, consider these alternatives:

  • Manufacturer savings programs — Novo Nordisk has patient savings programs that can reduce costs to $25-$150/month for qualifying non-government plan patients
  • Compounded semaglutide — Accessible from Minnesota-licensed pharmacies at lower prices, though BCBS won’t cover compounded versions
  • Ask about therapeutic alternatives — Blue Cross Blue Shield of Minnesota may prefer an alternative in the same class
  • Minnesota SPAP programs — Investigate if Minnesota provides supplemental prescription help for specialty drugs

Key Takeaway for Minnesota BCBS Members

Blue Cross Blue Shield of Minnesota may authorize Ozempic — the path to coverage is not automatic and depends on meeting specific clinical criteria. Your first step is reviewing your benefits and working with your provider to submit a complete PA request.

References

  1. FDA Prescribing Information for GLP-1 receptor agonists. U.S. Food and Drug Administration. 2024.
  2. SURPASS and SURMOUNT clinical trial programs. Eli Lilly and Company. 2022-2025.
  3. SUSTAIN and STEP clinical trial programs. Novo Nordisk. 2017-2024.
  4. American Diabetes Association Standards of Care in Diabetes. 2025.
  5. American Society of Health-System Pharmacists (ASHP) Drug Information. 2025.